Xeris Q2 revenue $92.1M (+29% YoY); Recorlev up 81%; tightens FY guidance to $385-390M

Xeris Biopharma Holdings, Inc.

Net product revenue $91.0M (+34% YoY); Recorlev $56.8M (+81%), Gvoke $22.5M (-4%), Keveyis $11.7M (+2%).
Net loss $31.1M includes ~$31M non-cash charge from 2028 Convertible Notes exchange; adjusted EBITDA $19.3M (+$6.7M YoY).
Gross margin improved to 86% (Q2 2025: 82%) on favorable product mix.
Full-year 2026 total revenue guidance tightened to $385-390M from prior range.
USPTO Notice of Allowance for new Keveyis patent expected to extend IP protection through at least 2039.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.